SUDEEPPHRM
Sudeep Pharma share price & financials
- Price
- ₹862.75
- Market cap
- ₹12.5k Cr
- Sector
- Healthcare
- Calls analysed
- 4
Sudeep Pharma Limited Q1 FY27
What went well
- Revenue of ₹158.3 crores, up 27% YoY, driven by broad-based performance across segments.
- EBITDA grew 25% YoY to ₹54.9 crores, maintaining a resilient margin of 34.7%.
- PAT increased 30% YoY to ₹40.6 crores, with PAT margin improving to 25.6%.
What to watch
- Challenging global operating environment characterized by geopolitical uncertainties, gas supply constraints, elevated logistics costs, and supply chain disruption.
- NSS (overseas subsidiary) had a challenging quarter due to a difficult European environment and customer demand impact.
What Sudeep Pharma Limited does
Sudeep Pharma manufactures mineral-based pharmaceutical excipients, fortificants and specialty nutrition ingredients (calcium and iron compounds, magnesium stearate, encapsulated and liposomal blends, premixes) used by pharma, food and nutrition companies worldwide. It earns by selling these ingredients to a global customer base spanning pharmaceutical, infant/medical/sports nutrition and functional-food manufacturers, supported by its own manufacturing units, global sales offices and warehouses. Through its wholly owned subsidiary Sudeep Pharma B.V. it acquired Nutrition Supplies Services (NSS) in Europe to expand its formulation and nutrition-market reach, and through Sudeep Advanced Materials it is building a new battery-grade iron phosphate business for the EV/energy-storage supply chain.
Segments
- Pharma, Food & Nutrition
- Specialty Ingredients
- Battery Materials (Sudeep Advanced Materials)
- Manufacturing sites
- 5 (4 in India at Nandesari, plus 1 in Ireland via the NSS acquisition)
- Combined annual manufacturing capacity
- ~1,23,000 MT (incl. upcoming Nandesari facility)
- Permanent employees
- 770+
- Customers
- 1,120+ across ~100 countries
- Product portfolio
- 100+ products across pharma, food & nutrition, specialty ingredients and battery materials
- Global warehouses
- 15 (USA, Europe, Africa, Asia)
Guidance record · Q1 FY27
what the last two calls moved 21 tracked 1 delivered 1 missed 19 open- Revenue Growth delivered, diluted said Q2 FY26 Promised: Sustain 26% growth for the remainder of the year. Q1 FY27: Promise concluded in the previous fiscal year (FY26).
- EBITDA Margin missed said Q2 FY26 Promised: Maintain above 35% going forward. Q1 FY27: Q1 FY27 EBITDA margin was 34.7%, remaining below the original >35% target.
- Working Capital Days revised down said Q2 FY26 Promised: Moderate and sustain approximately around 140 to 150 days over the medium term. Q1 FY27: Management revised near-term working capital target to 170 days (ex-battery), a dilution from the original 140-150 day medium-term goal.
All 21 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 32.5%, net profit up 36.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 149 | 83 | 105 | 80 | 88 −41% | 90 +8% | 80 −24% | 106 +33% |
| EBITDA | 63 | 26 | 45 | 30 | 31 −51% | 30 +15% | 29 −36% | 39 +30% |
| Net profit | 49 | 21 | 33 | 25 | 30 −39% | 27 +29% | 26 −21% | 34 +36% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +101.0% YTD
YTD: ₹598.55 on 1 Jan 2026 → ₹1,202.8. High ₹1,344.2 (8 Sept 2026), low ₹530 (20 Jan 2026).
How the price took the results
close before → close after
- Q1 FY27
- +10.0%
- 5 Aug
- Q4 FY26
- +0.8%
- 22 May
- Q3 FY26
- +3.3%
- 9 Feb
- Q2 FY26
- −3.3%
- 22 Dec
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
| Year ending | FY26 |
|---|---|
| Revenue | ₹338 Cr |
| Operating profit | ₹120 Cr |
| Operating margin | 35.5% |
| Interest | ₹6 Cr |
| Depreciation | ₹8 Cr |
| Net profit | ₹108 Cr |
| Net margin | 32.0% |
| Cash from operations | ₹96 Cr |
| Free cash flow | ₹30 Cr |
| ROCE | 21.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹10 Cr | ₹11 Cr |
| Reserves | ₹115 Cr | ₹167 Cr | ₹235 Cr | ₹333 Cr | ₹715 Cr | ₹775 Cr |
| Borrowings | ₹31 Cr | ₹73 Cr | ₹71 Cr | ₹60 Cr | ₹143 Cr | ₹127 Cr |
| Other liabilities | ₹67 Cr | ₹92 Cr | ₹109 Cr | ₹56 Cr | ₹121 Cr | ₹61 Cr |
| Total liabilities | ₹214 Cr | ₹333 Cr | ₹416 Cr | ₹451 Cr | ₹988 Cr | ₹974 Cr |
| Fixed assets | ₹68 Cr | ₹120 Cr | ₹90 Cr | ₹96 Cr | ₹299 Cr | ₹102 Cr |
| Capital work in progress | ₹23 Cr | ₹4 Cr | ₹26 Cr | ₹44 Cr | ₹126 Cr | ₹161 Cr |
| Investments | ₹24 Cr | ₹15 Cr | ₹19 Cr | ₹29 Cr | ₹0 Cr | ₹32 Cr |
| Other assets | ₹99 Cr | ₹194 Cr | ₹282 Cr | ₹282 Cr | ₹562 Cr | ₹679 Cr |
| Total assets | ₹214 Cr | ₹333 Cr | ₹416 Cr | ₹451 Cr | ₹988 Cr | ₹974 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Dec 2025, DIIs trimmed −1.95 pp while the public added +1.82 pp. The shareholder count shrank 18% to 35,695.
- Promoters
- 76.2%
- FIIs
- 1.8%
- DIIs
- 15.6%
- Public
- 6.4%
Since Dec 2025
- DIIs −1.95 pp
- Public +1.82 pp
- FIIs +0.14 pp
How it drifted, 3 quarters
Over this window DIIs fell from 17.6% to 15.6% — −1.9 pp.
Ownership split by quarter, oldest first. Dec '25: Promoters 76.2%, FIIs 1.7%, DIIs 17.6%, Public 4.6%.Mar '26: Promoters 76.2%, FIIs 1.6%, DIIs 18.1%, Public 4.2%.Jun '26: Promoters 76.2%, FIIs 1.8%, DIIs 15.6%, Public 6.4%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Sudeep Pharma Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Riva Resources Private Limited | 40.35% | unchanged |
| Bhayani Sujit Jaysukh | 21.16% | unchanged |
| Sujeet Jaysukh Bhayani Huf | 5.72% | unchanged |
| Avani Sujeet Bhayani | 4.47% | unchanged |
| Shanil Sujit Bhayani | 4.45% | unchanged |
| Nuvama Crossover Opportunities Fund - Series Iii AIF | 2.95% | −0.47 pp |
| Nuvama Crossover Opportunities Fund - Series Iii A . AIF | 2.57% | unchanged |
| Nuvama Crossover Opportunities Fund - Series Iii B . AIF | 2.14% | unchanged |
| Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund Mutual fund | 1.85% | unchanged |
| Mukul Mahavir Agrawal | 1.33% | unchanged |
| SBI Healthcare Opportunities Fund Mutual fund | 1.20% | unchanged |
| Aditya Energetic Trade Solution LLP | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in SUDEEPPHRM
Filings to Aug 2026
0 new, 3 added, 1 trimmed, 0 sold out — net −0.31 L shares (−0.7%).
- Held by funds
- ₹482 Cr
- 8 schemes
- Biggest holder
- SBI Healthcare Opportunities Fund
- ₹165 Cr · 2.8% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| SBI Healthcare Opportunities Fund SBI Mutual Fund | ₹165 Cr | held | Nov '25 |
| SBI MNC Fund SBI Mutual Fund | ₹83 Cr | held | Jul '26 |
| SBI Comma Fund SBI Mutual Fund | ₹83 Cr | held | Jul '26 |
| HDFC Manufacturing Fund HDFC Mutual Fund | ₹73 Cr | −0.32 L | Nov '25 |
| SBI Retirement Benefit Fund - Aggressive Plan SBI Mutual Fund | ₹53 Cr | +0.00 L | Jul '26 |
| SBI Retirement Benefit Fund - Aggressive Hybrid Plan SBI Mutual Fund | ₹23 Cr | +0.01 L | Jul '26 |
| SBI Retirement Benefit Fund - Conservative Hybrid Plan SBI Mutual Fund | ₹2 Cr | +0.00 L | Jul '26 |
| SBI Retirement Benefit Fund - Conservative Plan SBI Mutual Fund | ₹0 Cr | held | Jul '26 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Aug 2026
3 added, 1 trimmed — net −31,182 shares (−0.7%)
- Funds are sitting on
- +13%
- vs est. average cost
- Held by funds
- ₹482 Cr
- 8 schemes · ≈ 2.9% of the company
- Biggest holder
- SBI Healthcare Opportunities Fund
- ₹165 Cr · 2.8% of that fund
Shares held by these funds +291%
Nov '25 42.08 L shares Jul '26
What the price assumes
- Growth the price implies
- 51.9% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
All earnings calls (4)
Read the Q1 FY27 call →Learn to analyse Sudeep Pharma Limited
Guides on how to read this kind of business and the numbers that matter.